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Design and synthesis of multivalent α-1,2-trimannose-linked bioerodible
microparticles for applications in immune response studies of Leishmania
major infection
Abstract
Leishmaniasis, a neglected tropical disease, currently infects approximately 12 million people worldwide with
1 to 2 million new cases each year in predominantly underdeveloped countries. The treatment of the disease is
severely underdeveloped due to the ability of the Leishmania pathogen to evade and abate immune responses.
In an effort to develop anti-leishmaniasis vaccines and adjuvants, novel carbohydrate-based probes were made
to study the mechanisms of immune modulation. In this study, a new bioerodible polyanhydride
microparticle was designed and conjugated with a glycodendrimer molecular probe. This molecular probe
incorporates a pathogen-like multivalent display of α-1,2-trimannose, for which a more efficient synthesis was
designed, with a tethered fluorophore. Further attachment of the glycodendrimer to a biocompatible, surface
eroding microparticle allows for targeted uptake and internalization of the pathogen-associated
oligosaccharide by phagocytic immune cells. The α-1,2-trimannose-linked bioerodible microparticles were
found to be safe after administration into the footpad of mice and demonstrated a similar response to
α-1,2-trimannose-coated latex beads during L. major footpad infection. Furthermore, the bioerodible
microparticles allowed for investigation of the role of pathogen-associated oligosaccharides for recognition by
pathogen-recognition receptors during L. major-induced leishmaniasis.
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Abstract
Leishmaniasis, a neglected tropical disease, currently infects approximately 12 million people worldwide with 1 to 2 million new
cases each year in predominately underdeveloped countries. The treatment of the disease is severely underdeveloped due to the
ability of the Leishmania pathogen to evade and abate immune responses. In an effort to develop anti-leishmaniasis vaccines and
adjuvants, novel carbohydrate-based probes were made to study the mechanisms of immune modulation. In this study, a new
bioerodible polyanhydride microparticle was designed and conjugated with a glycodendrimer molecular probe. This molecular
probe incorporates a pathogen-like multivalent display of α-1,2-trimannose, for which a more efficient synthesis was designed, with
a tethered fluorophore. Further attachment of the glycodendrimer to a biocompatible, surface eroding microparticle allows for
targeted uptake and internalization of the pathogen-associated oligosaccharide by phagocytic immune cells. The α-1,2-trimannose-
linked bioerodible microparticles were found to be safe after administration into the footpad of mice and demonstrated a similar
response to α-1,2-trimannose-coated latex beads during L. major footpad infection. Furthermore, the bioerodible microparticles
allowed for investigation of the role of pathogen-associated oligosaccharides for recognition by pathogen-recognition receptors
during L. major-induced leishmaniasis.
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Figure 1: Leishmania lipophosphoglycan (LPG), with Gal-β-(1→4)-[Man-α-(1→2)-Man-α-(1→2)-Man] variant capping structure highlighted in blue and
R = H or species dependent oligosaccharide [25].
Introduction
Recognition of parasite cell surface molecules by host immune
cells initiates the first step in the immune response [1,2]. The
host’s immune system recognizes parasite surface glycoconju-
gates, or pathogen-associated molecular patterns (PAMPs), to
build an immune response against the parasite and impede
disease progression. Antigen presenting cells (APCs) recognize
these PAMPs as pathogenic as compared to host glycans
making these moieties feasible targets for both parasite detec-
tion and vaccine development [3].
Leishmania, an obligate intracellular parasite with varying sur-
face glycoconjugates, infects an estimated 12 million people
worldwide and has 350 million people at risk in endemic areas
(predominately in underdeveloped countries). The World
Health Organization estimates that this neglected tropical
disease causes between 1–2 million new cases annually [4].
Leishmaniasis manifests into three different forms, cutaneous,
mucosal, or visceral, depending on parasite species, host
immune system and location of infection [5]. Cutaneous, the
most common form, causes severe nodular and ulcerative skin
lesions, while mucocutaneous destroys mucus membranes, and
the most deadly form, visceral leishmaniasis, often results in
organ failure [6]. L. major, the parasite used in our in vivo
model, causes the cutaneous disease. In each pathogenesis, the
parasite infects and propagates in immune cells, the very cells
responsible for host protection. Through a range of mecha-
nisms not entirely understood, Leishmania subverts activation
of antimicrobial (nitric oxide) and cytokine inducible functions
that initiate effective immunity [5]. There are no approved anti-
leishmanial vaccines and the current therapeutics are toxic,
expensive and prone to induce resistance, such as, ampho-
tericin B (AmB), paromomycin and antimony-based chemother-
apeutics [7-9]. With growing resistance to antileishmanial drugs
and poor patient compliance, the development of safe,
efficacious and inexpensive alternatives to current therapeutics
is needed. Understanding the mechanisms by which
Leishmania regulates host immune responses are crucial for the
development of vaccines, which may induce adaptive
immunity that may prove beneficial for combating other intra-
cellular pathogens, such as Mycobacterium tuberculosis
[10,11].
Carbohydrate-based probes provide one method to investigate
parasitic mechanisms of immune suppression and evasion. The
cell surface glycoconjugates on Leishmania have been implicat-
ed in the ability of the parasite to infect host cells, then evade
and suppress host immune responses [5,12-15]. The most
prominent of these cell surface glycoconjugates, lipophospho-
glycan (LPG), consists of a glycosylphosphatidylinositol (GPI)
anchor and variable sugar capping structures (Figure 1) [15-20].
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Figure 2: Pathogen-associated bioerodible microparticles 2 and trimannose-coated latex beads 1.
The capping sugar tropisms vary with Leishmania species
(>20 species) and life stage of the pathogen, making it chal-
lenging to define how the capping sugars interact and modulate
host immune responses [21-24]. Since these cell-surface
glycans are structurally diverse and difficult to isolate in appre-
ciable quantities, synthetic pathogen-associated carbohydrate
probes are necessary to understand the LPG structure-to-func-
tion relationship. These synthetic oligosaccharides also provide
a structurally homogeneous standard to study how these glycans
interact with the host immune system in an effort to develop
effective anti-Leishmania vaccines.
Previously, discrete structural components of LPG have been
synthesized [26-38] and their involvement in modulating an
immune response of these reduced motifs has been investigated
[34-36,39]. The Pohl and Petersen groups have previously in-
vestigated how truncated oligosaccharide capping structures of
LPG interact with macrophage pattern recognition receptors
(PRRs) to modulate an innate immune response to L. major-in-
duced leishmaniasis in vitro and in vivo [11,40-42]. These
studies showed that a neutral α-1,2-trimannose capping struc-
ture alone is sufficient to modulate an innate immune response
through toll-like receptor 2 (TLR-2) and mannose receptor
(MR)-dependent pathways by increasing the production of
IL-12, a key cytokine involved in recruiting a T cell-mediated
adaptive immune response [11,40,42]. Furthermore, our acid-
labile probe was found to increase T cell production, suggesting
α-1,2-trimannose antigen presentation at the major histocompat-
ibility complex II (MHC II) [41].
Based on our previous studies [11,40-42], we sought to design
and synthesize a new Leishmania-associated molecular probe
that could allow intracellular monitoring and validation of T
cell antigen presentation. This new probe would also be linked
to the surface of a polyanhydride copolymer microparticle
based on 1,6-bis(p-carboxyphenoxy)hexane (CPH) and sebacic
anhydride (SA) to allow for enhanced internalization and uptake
of the immunogenic glycoconjugate through recognition by
phagocytic cells [43-45]. Here we discuss the design and syn-
thesis of this new bioerodible microparticle 2 compared to our
previously designed [11] trimannose-coated latex bead
construct 1 (Figure 2) and evaluate the biocompatibility of the
microparticle in spared dose administration to L. major infected
mice (Figure 4).
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626
Figure 3: General design of the bioerodible microparticles.
Results and Discussion
To further probe the biological mechanisms responsible for
L. major immune regulation, a new adjuvant-like pathogen-as-
sociated molecular probe was designed to promote pathogen
recognition receptor (PRR)-mediated internalization and slow
erosion in the acidic phagolysosome of macrophages. This
bioerodible microparticle 2 design evolved from earlier synthe-
tic probes with improved translatability for therapeutic develop-
ment [11,41,42]. To mimic the Leishmania pathogen, the size of
our probe needed to be approximately the same size as the
pathogen (1 μm in diameter) and provide a multivalent display
of the synthetic α-1,2-trimannose similar to the Leishmania
promastigote cell-wall glycans. Furthermore, a tethered fluoro-
phore would allow for immunofluorescence assays, intracel-
lular trafficking, and validation of T cell-mediated antigen
recognition. To allow for both surface functionalization of this
glycan to the bioerodible microparticles and conjugation of the
fluorophore, two amine handles would be necessary (Figure 3).
The design would also benefit from the development of a more
efficient synthesis of the mannose oligomer sidechain.
From the general design elements in Figure 3, we proposed the
following synthetic motifs. For PRR binding, a dendrimeric
scaffold provides a multivalent display of the α-1,2-trimannose
glycoconjugate, similar to Leishmania LPG and additionally
may promote glycodendrimer antigen presentation when hydro-
lyzed in the acidic phagolysosome [39,41,46]. To improve the
overall synthetic sequence from our previous syntheses
[11,41,42], an amino alcohol spacer was utilized to connect the
trimannose reducing end to the dendrimer by means of amide
bond coupling. Furthermore, the amino alcohol spacer provides
a handle for the incorporation of a fluorous-tag for ease of
purification by fluorous solid phase-extraction (FSPE). The use
of the fluorous tag enables solution-phase automated synthesis
of α-1,2-trimannose in the future as shown previously with a
related spacer and fluorous tag [47]. Incorporation of the com-
mercially available rhodamine dye, TAMRA (555ex/580em), to
the dendrimer would allow for standard immunofluorescence
assays, to track the microparticle following cellular uptake and
intracellular processing. TAMRA’s high photostability, low pH
sensitivity and ease of incorporation through amide bond cou-
pling, facilitates synthetic manipulation and biocompatibility
[48,49].
In an effort to make a direct comparison to our previous biolog-
ical studies, trimannose-coated latex beads also were synthe-
sized using 1 μm FluoSpheres© carboxylate-modified latex
beads labeled with a red fluorophore (emission maximum
580 nm). The latex-bead synthesis was modified slightly from
previous synthesis for improved ease of synthesis of triman-
nose and comparability to this study’s bioerodible microparti-
cles by coupling the reducing end of trimannose with the afore-
mentioned amino alcohol spacer [11,41]. Biological analysis of
the trimannose-coated latex beads was described previously
[42] and used to compare the new construct.
Synthesis of α-1,2-trimannose
The synthesis of α-1,2-trimannose, required for both the glyco-
dendrimer 2 and latex beads 1, was achieved through iterative
glycosylation with known trichloroacetimidate mannosyl
donors 3 and 4 [47,50] and the use of a fluorous tag containing
an amino alcohol spacer rather than an alkene that would
require late-stage modifications. The aminopentanol spacer 6
used at the reducing end to conjugate to the dendrimer was first
protected with fluorous CbzF-NHS 5 to allow for purification
by FSPE of the mannosyl intermediates and to facilitate future
automated syntheses to produce α-1,2-trimannose in appre-
ciable quantities similar to previous efforts (Scheme 1)
[11,47,51].
To synthesize the oligosaccharide, activation of TCA donor 3
with TMSOTf and glycosylation of the CbzF-protected
aminopentanol 7 afforded the monosaccharide 8 (Scheme 2).
The 2-O-position was then deacylated, followed by iterative
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Scheme 1: Synthesis of fluorous CbzF-protected aminopentanol spacer 7.
Scheme 2: Iterative synthesis of α-1,2-trimannose 16. Reagents and conditions: a) 1 M NaOH, MeOH or NaOMe.
glycosylation/deacetylation with donor 3 to provide dimanno-
side acceptor 11. TCA-mannose donor 3 was initially used to
cap the dimannoside 11. However, hydrogenolysis of the benzyl
ethers under continuous flow (0.3–1 mL/min) and H2 pressure
(30–60 bar) using an H-cube apparatus was found to be effec-
tive at removing the benzyl ethers, but arduously slow (>48 h)
from the limited surface-mediated interactions with the Pd/C
cartridge. By comparison, batch hydrogenolysis at 1 atm pres-
sure hydrogen afforded the fully deprotected trimanose 16 in
just 24 h. To further reduce the total number of benzyl groups,
the simpler peracylated TCA donor 4 was used to cap the oligo-
saccharide.
The benzyl-protected nitrogen proved unnecessary and was
difficult to deprotect under these conditions. Therefore, future
applications to automated syntheses will exclude this nitrogen
protecting group. The light chain fluorous CbzF tag was advan-
tageous in reducing the number of steps to a readily conjugate-
able molecule for particle functionalization compared to that of
our previously used alkene fluorous tag [11,52,53]. The CbzF
tag was also removed during global deprotection to readily
provide an amine handle for conjugation to the dendrimeric
core, avoiding further synthetic manipulations.
Synthesis of glycodendrimer
Attachment of the 5(6)-TAMRA fluorophore to the dendrimeric
core allowed for various potential linkage options in addition to
providing the amine handle for microparticle surface functional-
ization. Unfortunately, the sterically encumbered tertiary amine
of the dendrimer prevented simple coupling of commercially
Beilstein J. Org. Chem. 2019, 15, 623–632.
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Scheme 3: Synthesis of bioerodible microparticle 2. Reagents and conditions: a) Et2NH, CH3CN, b) CH2Cl2/TFE/AcOH 3:1:1, c) TFA/THF/H2O
90:8:2, d) Et2NH, DMF, e) CPH/SA microparticles 20:80, EDCI, NHS, H2O.
available Nα-TAMRA-Nε-Teoc-L-lysine to the dendrimer.
Therefore, we settled on first coupling Nα-Fmoc-Nε-(4-methyl-
trityl)-L-lysine (17) to the dendrimeric amine 18 by standard
HATU amide coupling conditions (Scheme 3).
The protecting groups were chosen specifically for selective
deprotection and compatibility with the TAMRA fluorophore,
which is stable to acidic and basic conditions, but incompatible
with reducing conditions. To conserve the relatively expensive
TAMRA fluorophore and prevent loss through the synthetic se-
quence, amino linkers were first conjugated to the dendrimer
core. The Nα-Fmoc group of 19 was first removed and coupled
to Nε-Fmoc-aminohexanoic acid 21 to afford the elaborated
dendrimer core 22. The aminohexanoic acid would eventually
provide the amino handle for the attachment to the surface of
the microparticle and was considered sufficient in chain length
to perform the functionalization. The 4-methyltrityl (Mtt) group
was selectively hydrolyzed with CH2Cl2/TFE/AcOH 3:1:1 and
trapped by triethylsilane, providing free amine 23 [54]. At this
point, the epsilon amine 23 was coupled with TAMRA-NHS,
followed by acidic deprotection of the tert-butyl esters to afford
the triacid 25. Then, the successful coupling of the deprotected
trimannose 16 to the dendrimeric core 25 provided the glyco-
dendrimer 26. For the attachment of the glycodendrimer to the
microparticle surface, the amino Fmoc was removed then
coupled via EDCI/NHS to afford the desired bioerodible glyco-
dendrimer microparticle 2.
In vivo assessment of bioerodible glycoden-
drimer
To evaluate the safety and feasibility of the trimannose
bioerodible microparticles 2 in vivo during L. major infection,
we inoculated C57BL/6 wild type (WT) and mannose receptor
deficient (MR−/−) mice with L. major parasites alone, triman-
nose bioerodible microparticles 2 alone, or L. major parasites
and trimannose bioerodible microparticles 2 in a single inocula-
tion on day 0 in a manner similar to previous studies using
trimannose-coated latex beads 1 [42]. Lesions were measured
weekly and allowed to progress to day 42 post-infection to
provide a time course comparable to previous studies [42]. Mice
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inoculated with bioerodible microparticles 2 in the absence of
L. major parasites showed insignificant changes in footpad
thickness indicating no untoward response to these particles
(Figure 4, unfilled squares and triangles). This is consistent with
prior studies which have demonstrated that polyanhydride
microparticles do not cause significant levels of inflammation
[55], as well as prior studies that the trimannose on a latex bead
1 is not inflammatory in the absence of an infection [40,42].
Fortunately, the newly designed probe with TAMRA did not
elicit a large inflammatory response that would preclude its use
as a biological probe.
Figure 4: Trimannose-linked bioerodible microparticle 2 treatment of
Leishmania major infected wild-type and mannose receptor deleted
C57BL/6 mice reduces footpad lesion size. Footpad lesion size is in
millimeters for wild-type (WT) and mannose receptor deleted (MR−/−)
mice inoculated with L. major alone (Lm, grey circle MR−/−), L. major
and trimannose bioerodible microparticles 2 (Lm + tri: blue triangle WT,
black square MR−/−), or trimannose bioerodible microparticles 2 alone
(Tri: unfilled squares MR−/−, unfilled triangles WT). Footpad lesion size
was determined by calculating difference between inoculated left hind
footpad and non-inoculated right hind footpad. n = 6–10 mice per
group. One-way ANOVA with Tukey’s post-hoc test.
As shown by Akilov et al. [56] and Grinnage-Pulley et al. [42],
mannose receptor deleted mice develop L. major infections sim-
ilar to wild-type mice. L. major infected MR −/− mice de-
veloped progressive footpad inflammation as early as 21 days
post-infection that continued through 42 days post-infection
(grey circles and black squares). MR−/− mice infected with
L. major and bioerodible microparticles 2 (black squares) had
lesions of a similar size to MR−/− mice given L. major alone.
These mice do not have the carbohydrate specific receptor to
recognize the trimannose and alter the inflammatory response,
so no difference in footpad lesion from L. major alone was ex-
pected to occur in these mice as seen in previous studies [42].
WT mice receiving L. major and bioerodible microparticles 2
developed lesions, but these lesions were smaller, although not
significantly different, than the sizes of lesions found in infected
MR−/− mice at day 42 post-infection. These results are consis-
tent with findings using trimannose-coated latex beads 1 [42].
Infected, trimannose treated, WT mice developed lesions, but
the lesion size was significantly decreased at peak infection, and
these mice had smaller, but not significantly decreased lesions
42 days post-infection. Due to limited availability of MR−/−
mice, both WT and MR−/− mice were older than in prior
studies, which may have resulted in the non-significant lesion
size difference. The similar decreased response in infected
trimannose treated wild-type mice in both the latex bead 1 and
bioerodible microparticle 2 studies suggests that the new
trimannose-linked bioerodible microparticles 2 are a safe and
viable tool for presenting glycodendrimers to mammalian
immune systems.
The new construct of the bioerodible microparticle allows for
investigation into the mechanisms of pathogen-recognition via
MR and TLR2/4 and antigen presentation by APCs. Further-
more, it is anticipated that the glycodendrimer microparticles
could provide spared dose vaccination or adjuvant therapy
against L. major leishmaniasis, which will be evaluated in
future work. Preliminary biological studies reported here show
that indeed bioerodible microparticles 2 have an effect similar
to our previously designed latex beads 1 [42] and should be safe
for more extensive animal studies. Future studies using the
bioerodible microparticles 2 will include optimization of the
relative dosing of bioerodible microparticles 2 as compared to
the trimannose-coated latex beads 1. Previously trimannose-
coated latex beads 1 were inoculated into mouse footpads at
days 0, 7, 14 and 21 for a total of 2.0 × 108 trimannose-coated
beads 1 [42]. We designed the bioerodible microparticles 2 to
allow a single delivery of trimannose from a total of 5 × 107
particles, a four-fold lower level than what was used for the
latex bead study [42], as studies by Huntimer and co-workers
showed in 2013 that the CPH:SA polymer provided inherent
adjuvant properties and dose sparing effects [57]. In light of
these in vivo feasibility results, the first optimization studies
should evaluate dosing for bioerodible microparticles 2 with
single inoculations of 2×, 3×, and 4× higher amounts than the 5
× 107 microparticle dose used here to see if a more significant
change can be observed. Additional studies evaluating altered
particle degradation rate(s) and encapsulation of trimannose
within the particle could also be performed to provide sustained
release of the trimannose.
Conclusion
Herein we described our newly designed pathogen-associated
bioerodible microparticle 2 for investigation into the mecha-
nisms of L. major immune suppression and evasion. The fluo-
rescent-tagged pathogen-associated oligosaccharide probe was
synthesized through orthogonal conjugation for ease of attach-
Beilstein J. Org. Chem. 2019, 15, 623–632.
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ment to bioerodible microparticles. The PAMP carbohydrate 16
was further synthesized through iterative glycosylation and
FSPE purification to rapidly afford appreciable and pure quanti-
ties in fewer steps than prior work enabled by the Cbz F-tag that
allows for solution-phase automated synthesis in the future.
In conclusion, these newly synthesized α-1,2-trimannose-linked
bioerodible microparticles 2 are a feasible construct for deliv-
ering trimannose to L. major infected mice and will be a more
translatable therapeutic target moving forward. We anticipate
that further studies will allow for elucidation of the effect of
these pathogen-associated molecular patterns of LPG to investi-
gate the intracellular environment and mechanisms for immune
suppression and evasion; the new construct of the bioerodible
microparticle allows for investigation into the mechanisms of
pathogen-recognition via MR and TLR2/4 and antigen presenta-
tion by APCs. Furthermore, it is anticipated that the glycoden-
drimer microparticles could provide spared dose vaccination or
adjuvant therapy against L. major leishmaniasis, which will be
evaluated in future work.
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